These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nevada
|
26-1407544
|
|
|
(State or other jurisdiction
of incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
| Large accelerated filer | o | Non-accelerated filer | o |
| Accelerated filer | o | Smaller reporting company | þ |
|
Item 1.
|
Financial Statements. | 4 | |||
|
Item 2.
|
Management's Discussion and Analysis of Financial Condition and Results of Operations.
|
21 | |||
|
Item 3.
|
Quantitative and Qualitative Disclosures about Market Risk.
|
26 | |||
|
Item 4.
|
Controls and Procedures.
|
27 | |||
|
PART II--OTHER INFORMATION
|
|||||
|
Item 1.
|
Legal Proceedings.
|
28 | |||
|
Item 1A.
|
Risk Factors.
|
28 | |||
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds.
|
28 | |||
|
Item 3.
|
Defaults Upon Senior Securities.
|
28 | |||
|
Item 5.
|
Other Information.
|
28 | |||
|
Item 6.
|
Exhibits.
|
29 | |||
|
SIGNATURES
|
30 | ||||
|
March 31,
2012
|
December 31,
2011
|
|||||||
|
unaudited
|
audited
|
|||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 111,654 | $ | 249,466 | ||||
|
Accounts receivable, less allowance of $178,370 and $143,089, respectively
|
2,008,126 | 1,379,668 | ||||||
|
Inventories
|
3,122,006 | 3,981,997 | ||||||
|
Prepaid expenses
|
561,361 | 491,308 | ||||||
|
Other current assets
|
921,029 | 1,026,477 | ||||||
|
Total current assets
|
6,724,176 | 7,128,916 | ||||||
|
Property, plant and equipment, net
|
15,712,486 | 15,530,905 | ||||||
|
Assets held for sale
|
885,000 | 885,000 | ||||||
|
Goodwill and intangible assets
|
2,767,994 | 2,767,994 | ||||||
|
Other assets
|
937,588 | 905,106 | ||||||
| Total assets | $ | 27,027,244 | $ | 27,217,921 | ||||
|
Liabilities and stockholders' deficit
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$ | 15,460,576 | $ | 14,337,536 | ||||
|
Current portion of long term secured notes
|
3,025,588 | 2,425,588 | ||||||
|
Secured notes, net of discount for issuance costs
|
5,574,849 | 5,161,191 | ||||||
|
Short term notes and unsecured working capital lines of credit
|
4,466,866 | 2,066,720 | ||||||
|
Mandatorily redeemable Series B convertible preferred stock
|
2,345,565 | 2,320,164 | ||||||
|
Other current liabilities
|
3,135,969 | 3,116,868 | ||||||
|
Total current liabilities
|
34,009,413 | 29,428,067 | ||||||
|
Long term liabilities:
|
||||||||
|
Long term portion of secured notes, net of discount for issuance costs
|
16,827,845 | 15,701,023 | ||||||
|
Long term unsecured debt (related party), net of discount for issuance costs
|
4,723,990 | 4,291,913 | ||||||
|
Total long term liabilities
|
21,551,835 | 19,992,936 | ||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders' deficit:
|
||||||||
|
Series B convertible preferred stock, $0.001 par value; 7,235,565 authorized; 3,097,725 and 3,115,225 shares
issued and outstanding, respectively (aggregate liquidation preference of $9,293,175 and $9,345,675 respectively) |
3,097 | 3,115 | ||||||
|
Common Stock, $0.001 par value; 400,000,000 authorized; 132,054,503 and
|
||||||||
|
130,746,890 shares issued and outstanding, respectively
|
132,054 | 130,747 | ||||||
|
Additional paid-in capital
|
47,153,711 | 45,432,447 | ||||||
|
Accumulated deficit
|
(73,890,487 | ) | (65,526,029 | ) | ||||
|
Accumulated other comprehensive loss
|
(1,932,379 | ) | (2,243,362 | ) | ||||
|
Total stockholders' deficit
|
(28,534,004 | ) | (22,203,082 | ) | ||||
|
Total liabilities and stockholders deficit
|
$ | 27,027,244 | $ | 27,217,921 | ||||
|
For the three months ending March 31,
|
||||||||
|
2012
|
2011
|
|||||||
|
Revenues
|
$ | 44,195,776 | $ | 738,469 | ||||
|
Cost of goods sold
|
46,454,288 | 787,472 | ||||||
|
Gross loss
|
(2,258,512 | ) | (49,003 | ) | ||||
|
Research and development expenses
|
192,617 | 32,569 | ||||||
|
Selling, general and administrative expenses
|
1,962,841 | 2,103,409 | ||||||
|
Operating loss before income tax
|
(4,413,970 | ) | (2,184,981 | ) | ||||
|
Other income / (expense)
|
||||||||
|
Interest income
|
348 | 4,021 | ||||||
|
Interest expense
|
(3,965,047 | ) | (2,103,163 | ) | ||||
|
Other income, net of expenses
|
18,211 | 24,031 | ||||||
|
Loss before income taxes
|
(8,360,458 | ) | (4,260,092 | ) | ||||
|
Income taxes
|
(4,000 | ) | (3,200 | ) | ||||
|
Net loss
|
$ | (8,364,458 | ) | $ | (4,263,292 | ) | ||
| Other comprehensive loss | ||||||||
|
Foreign currency translation adjustment
|
310,983 | 20,286 | ||||||
|
Comprehensive loss
|
$ | (8,053,475 | ) | $ | (4,243,006 | ) | ||
|
Loss per common share
|
||||||||
|
Basic and diluted
|
$ | (0.06 | ) | $ | (0.05 | ) | ||
|
Weighted average shares outstanding
|
||||||||
|
Basic and diluted
|
131,128,280 | 90,789,254 | ||||||
|
For the three months ended March 31,
|
||||||||
|
2012
|
2011
|
|||||||
|
Operating activities:
|
||||||||
|
Net loss
|
$ | (8,364,458 | ) | $ | (4,263,292 | ) | ||
|
Adjustments to reconcile net loss to
net cash provided by/(used in) operating activities:
|
||||||||
|
Stock-based compensation
|
70,915 | 53,421 | ||||||
|
Amortization and depreciation
|
344,917 | 189,789 | ||||||
|
Amortization of debt discount
|
1,296,855 | 1,483,786 | ||||||
|
Loss on extinguishment of debt
|
- | 33,926 | ||||||
|
Loss on disposal of assets
|
38,209 | - | ||||||
|
Changes in assets and liabilities:
|
||||||||
|
Accounts receivable
|
(598,341 | ) | 96,013 | |||||
|
Inventory
|
908,994 | 477,841 | ||||||
|
Prepaid expenses
|
13,904 | 117,113 | ||||||
|
Other current assets and other assets
|
113,402 | (29,817 | ) | |||||
|
Accounts payable
|
1,048,540 | 1,307,362 | ||||||
|
Accrued interest expense
|
2,216,220 | 536,478 | ||||||
|
Other liabilities
|
(39,634 | ) | 56,794 | |||||
|
Net cash provided by/(used in) operating activities
|
(2,950,477 | ) | 59,414 | |||||
|
Investing activities:
|
||||||||
|
Purchase of property, plant and equipment, net
|
(32,711 | ) | (1,708,729 | ) | ||||
|
Net cash (used in) investing activities
|
(32,711 | ) | (1,708,729 | ) | ||||
|
Financing activities:
|
||||||||
|
Proceeds from borrowings under secured short term debt facilities
|
- | 1,750,776 | ||||||
|
Repayments of borrowings under secured short term debt facilities
|
(200,000 | ) | - | |||||
|
Proceeds from borrowings under unsecured short term notes and
working capital lines of credit
|
3,859,609 | - | ||||||
|
Repayments of borrowings under unsecured working capital facilities
|
(898,605 | ) | (538,614 | ) | ||||
|
Net cash provided by financing activities
|
2,761,004 | 1,212,162 |
| Effect of exchange rate changes on cash and cash equivalents | 84,372 | (7,746 | ) | |||||
|
Net decrease in cash and cash equivalents
|
(137,812 | ) | (444,899 | ) | ||||
|
Cash and cash equivalents at beginning of period
|
249,466 | 683,016 | ||||||
|
Cash and cash equivalents at end of period
|
$ | 111,654 | $ | 238,117 | ||||
|
Supplemental disclosures of cash flow information, cash paid:
|
||||||||
|
Interest, net of capitalized interest of $0 in 2012 and $155,670 in 2011
|
$ | 297,487 | $ | 102,951 | ||||
|
Interest to related party
|
93,173 | - | ||||||
|
Income taxes
|
4,000 | 3,200 | ||||||
|
Supplemental disclosures of cash flow information, non-cash transactions:
|
||||||||
|
Payment of principal and interest through the issuance of stock
|
$ | 957,044 | $ | 363,959 | ||||
|
Issuance of warrants to subordinated debt holders
|
690,948 | - |
|
1.
|
Nature of Activities and Summary of Significant Accounting Policies
|
|
●
|
Aemetis Americas, Inc. (formerly “American Ethanol, Inc.”), a Nevada corporation and its subsidiaries Sutton Ethanol, LLC, a Nebraska limited liability company, Illinois Valley Ethanol, LLC, an Illinois limited liability company, Danville Ethanol, Inc., an Illinois corporation, and AE Biofuels, Inc., a Delaware corporation;
|
|
●
|
Biofuels Marketing, a Delaware corporation;
|
|
●
|
Aemetis International, Inc. (formerly International Biodiesel, Inc.), a Nevada corporation and its subsidiary International Biofuels, Ltd., a Mauritius corporation and its subsidiary Universal Biofuels Private, Ltd., an India company;
|
|
●
|
Aemetis Technologies, Inc. (formerly AE Zymetis, Inc.), a Delaware corporation;
|
|
●
|
Aemetis Biochemicals, Inc., a Nevada corporation;
|
|
●
|
Aemetis Biofuels, Inc. (formerly AE Biofuels Technologies, Inc.), a Delaware corporation and its subsidiary Energy Enzymes, Inc., a Delaware corporation;
|
|
●
|
AE Advanced Fuels, Inc., a Delaware corporation;
|
|
●
|
Aemetis Advanced Fuels, Inc., a Nevada corporation; and,
|
|
●
|
Aemetis Advanced Fuels Keyes, Inc. (formerly AE Advanced Fuels Keyes, Inc.), a Delaware corporation.
|
|
For the three months ended
|
||||||||
|
March 31, 2012
|
March 31, 2011
|
|||||||
|
Aemetis Series B preferred stock
|
3,108,687 | 3,748,559 | ||||||
|
Aemetis Series B warrants
|
351,402 | 443,853 | ||||||
|
Aemetis Common stock options and warrants
|
8,961,642 | 7,194,041 | ||||||
|
Convertible interest & fees on note – related party
|
413,898 | 23,004,243 | ||||||
|
Convertible promissory note
|
171,219 | - | ||||||
|
Total weighted average number of potentially dilutive shares excluded from the diluted net loss per share calculation
|
13,006,848 | 34,390,696 | ||||||
|
●
|
The “India” operating segment encompasses the Company’s 50 million gallon per year (MGY) nameplate capacity biodiesel plant in Kakinada, India, the administrative offices in Hyderabad, India, and the holding companies in Nevada and Mauritius.
|
|
●
|
The “North America” operating segment includes the Company’s leased 55 MGY nameplate capacity ethanol plant in Keyes, California and the assets (principally land) held for sale in Sutton, Nebraska and in Danville, Illinois.
|
|
●
|
The “Other” segment encompasses the Company’s costs associated with new market development, company-wide fund raising, formation, executive compensation and other corporate expenses.
|
|
2.
|
Inventory
|
|
March 31,
2012
|
December 31,
2011
|
|||||||
|
Raw materials
|
$ | 921,883 | $ | 628,366 | ||||
|
Work-in-progress
|
1,648,599 | 2,056,771 | ||||||
|
Finished goods
|
551,524 | 1,296,860 | ||||||
|
Total inventory
|
$ | 3,122,006 | $ | 3,981,997 | ||||
|
3.
|
Property, Plant and Equipment
|
|
March 31,
2012
|
December 31,
2011
|
|||||||
|
Land
|
$ | 695,294 | $ | 667,008 | ||||
|
Buildings
|
14,039,843 | 10,429,402 | ||||||
|
Furniture and fixtures
|
155,500 | 152,373 | ||||||
|
Machinery and equipment
|
1,136,587 | 1,025,105 | ||||||
|
Leasehold/Tenant Improvements
|
2,833,050 | 2,800,339 | ||||||
|
Construction in progress
|
- | 3,186,551 | ||||||
|
Total gross property, plant & equipment
|
18,860,274 | 18,260,778 | ||||||
|
Less accumulated depreciation
|
(3,147,788 | ) | (2,729,873 | ) | ||||
|
Total net property, plant & equipment
|
$ | 15,712,486 | $ | 15,530,905 | ||||
|
4.
|
Notes Payable
|
|
March 31,
2012
|
December 31,
2011
|
|||||||
|
Third Eye Capital senior secured term notes, including accrued interest of $2,113,121 and revenue participation of $6,953,065 less unamortized issuance discount of $779,360 for March 31, 2012 and accrued interest of $1,593,378 and revenue participation of $5,277,753 less unamortized issuance discount of $513,943 for December 31, 2011. For the three months ending March 31, 2012, the Company issued 1,093,925 of debt discount shares.
|
$ | 19,853,433 | $ | 18,126,611 | ||||
|
State Bank of India secured term loan, including accrued interest of $1,740,287 and $1,485,614 less unamortized issuance discount of $12,418 and $14,902, respectively.
|
5,574,849 | 5,161,191 | ||||||
|
Revolving line of credit (related party), including accrued interest of $1,428,405 and $1,428,403 less unamortized issuance discount of $441,216 and $873,322, respectively.
|
4,723,990 | 4,291,913 | ||||||
|
Sub-debt notes, including accrued interest of $37,500 and $0 less unamortized issuance discount of $619,334 and $0, respectively.
|
2,418,166 | - | ||||||
|
Unsecured working capital loans and short-term notes, including accrued interest of $95,968 and $103,382, respectively.
|
2,048,700 | 2,066,720 | ||||||
|
Total debt
|
34,619,138 | 29,646,435 | ||||||
|
Less current portion of debt
|
13,067,303 | 9,653,499 | ||||||
|
Total long term debt
|
$ | 21,551,835 | $ | 19,992,936 | ||||
|
For the 12 months ended
|
Debt Repayments
|
|||
|
March 31, 2013
|
$ | 13,067,303 | ||
|
March 31, 2014
|
10,404,013 | |||
|
March 31, 2015
|
11,147,822 | |||
|
Total
|
$ | 34,619,138 | ||
|
5.
|
Operating Leases
|
|
For the twelve months ended March 31,
|
Future Rent
Payments
|
|||
|
2013
|
1,150,596 | |||
|
2014
|
398,877 | |||
|
2015
|
360,282 | |||
|
Total
|
$ | 1,909,755 | ||
|
6.
|
Outstanding Warrants
|
|
Preferred Stock
|
Warrants Issued &
Outstanding
|
Weighted - Average
Exercise Price
|
Warrants Issued &
Exercisable
|
Average Remaining
Term in Years
|
||||||||||||
|
Outstanding December 31, 2011
|
392,479 | $ | 3.00 | 392,479 | 0.25 | |||||||||||
|
Expired
|
(363,282 | ) | 3.00 | (363,282 | ) | |||||||||||
|
Outstanding March 31, 2012
|
29,197 | 3.00 | 29,197 | 0.27 | ||||||||||||
|
Common Stock
|
Warrants Issued
&
Outstanding
|
Weighted - Average
Exercise Price
|
Warrants Issued
&
Exercisable
|
Average Remaining
Term in Years
|
||||||||||||
|
Outstanding December 31, 2011
|
1,428,590 | $ | 0.790 | 1,428,590 | 3.34 | |||||||||||
|
Expired
|
(5,000 | ) | 3.000 | (5,000 | ) | |||||||||||
|
Granted
|
1,000,000 | 0.001 | 1,000,000 | |||||||||||||
|
Exercised
|
(166,667 | ) | 0.001 | (166,667 | ) | |||||||||||
|
Outstanding March 31, 2012
|
2,256,923 | 0.22 | 2,256,923 | 3.56 | ||||||||||||
| Total |
Warrants Issued
&
Outstanding
|
Weighted - Average
Exercise Price
|
Warrants Issued
&
Exercisable
|
Average Remaining
Term in Years
|
||||||||||||
|
Outstanding December 31, 2011
|
1,821,069 | $ | 1.27 | 1,821,069 | 2.67 | |||||||||||
|
Expired
|
(368,282 | ) | 3.000 | (368,282 | ) | |||||||||||
|
Granted
|
1,000,000 | 0.001 | 1,000,000 | |||||||||||||
|
Exercised
|
(166,667 | ) | 0.001 | (166,667 | ) | |||||||||||
|
Outstanding March 31, 2012
|
2,286,120 | 0.26 | 2,286,120 | 3.52 | ||||||||||||
|
7.
|
Agreements
|
| Three months ended March 31, | ||||||||
|
2012
|
2011
|
|||||||
|
Ethanol sales
|
32,053,209 | - | ||||||
|
Wet distiller's grains sales
|
7,831,741 | - | ||||||
|
Corn purchases
|
36,784,805 | - | ||||||
|
Accounts receivable
|
824,881 | - | ||||||
|
8.
|
Segment Information
|
|
Statement of Operations Data
|
Three months ended March 31,
|
|||||||
|
2012
|
2011
|
|||||||
|
Revenues
|
||||||||
|
India
|
$ | 2,313,697 | $ | 738,469 | ||||
|
North America
|
41,882,079 | - | ||||||
|
Other
|
- | - | ||||||
|
Total revenues
|
$ | 44,195,776 | $ | 738,469 | ||||
|
Cost of goods sold
|
||||||||
|
India
|
$ | 2,407,589 | 787,303 | |||||
|
North America
|
44,046,699 | 169 | ||||||
|
Other
|
- | - | ||||||
|
Total cost of goods sold
|
$ | 46,454,288 | $ | 787,472 | ||||
|
Gross profit (loss)
|
||||||||
|
India
|
$ | (93,892 | ) | $ | (48,834 | ) | ||
|
North America
|
(2,164,620 | ) | (169 | ) | ||||
|
Other
|
- | - | ||||||
|
Total gross loss
|
$ | (2,258,512 | ) | $ | (49,003 | ) | ||
|
March 31,
2012
|
December 31,
2011
|
|||||||
|
India
|
$ | 16,281,257 | $ | 15,654,763 | ||||
|
North America (United States)
|
10,745,857 | 11,563,132 | ||||||
|
Other
|
130 | 26 | ||||||
|
Total Assets
|
$ | 27,027,244 | $ | 27,217,921 | ||||
|
9.
|
Related Party Transactions
|
|
10.
|
Subsequent Events
|
|
Cash
|
$ | 16,500 | ||
|
Fair value of shares issued
|
15,600 | |||
|
Contingent Consideration
|
3,824 | |||
| $ | 35,924 |
|
Tangible Assets:
|
||||
|
Accounts receivable
|
$ | 3,114 | ||
|
Prepaid assets
|
5 | |||
|
Equipment held for resale
|
1,367 | |||
|
Property, plant and equipment
|
70,464 | |||
|
Other assets
|
147 | |||
|
Total Tangible Assets Acquired
|
75,097 | |||
|
Liabilities Assumed
|
||||
|
Accounts payable
|
(6 | ) | ||
|
Identified Intangible Assets
|
||||
|
Permits
|
926 | |||
|
Net Assets Acquired
|
$ | 76,017 | ||
|
Historical
|
Pro Forma
|
|||||||||||||||
|
Aemetis, Inc.
|
Cilion, Inc.
|
Adjustments
|
Combined
|
|||||||||||||
|
For the three months ending March 31, 2011
|
||||||||||||||||
|
Revenue
|
$ | 738 | $ | - | $ | - | $ | 738 | ||||||||
|
Net Income
|
(4,263 | ) | (717 | ) | 40,103 | 35,123 | ||||||||||
|
For the three months ending March 31, 2012
|
||||||||||||||||
|
Revenue
|
44,196 | 900 | (900 | ) | 44,196 | |||||||||||
|
Net Income
|
$ | (8,364 | ) | $ | 593 | $ | 333 | $ | (7,438 | ) | ||||||
|
11.
|
Management’s Plan
|
|
●
|
As discussed in the subsequent event footnote, the acquisition of Cilion provided the Company with a substantial asset to use as collateral both with their current lender and with future financings.
|
|
●
|
Continue to work with the Company’s senior lender to provide financing as well as explore other financing arrangements including working with Advanced BioEnergy LP to attract investors for the remaining $35 million of notes available under the program, or through the issuance of additional equity.
|
|
●
|
Development of Joint Venture agreements for the expansion of the Company’s technologies.
|
|
●
|
Continued support from major shareholders and board of directors in providing cash financing.
|
|
●
|
Overview
. Discussion of our business and overall analysis of financial and other highlights affecting us to provide context for the remainder of MD&A.
|
|
●
|
Results of Operations
. An analysis of our financial results comparing the three months ended March 31, 2012 to the three months ended March 31, 2011.
|
|
●
|
Liquidity and Capital Resources
. An analysis of changes in our balance sheets and cash flows and discussion of our financial condition.
|
|
●
|
Critical Accounting Estimates
. Accounting estimates that we believe are important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.
|
|
2012
|
2011
|
Increase/(Decrease)
|
||||||||||
|
North America
|
$ | 41,882 | - | $ | 41,882 | |||||||
|
India
|
$ | 2,314 | $ | 738 | 1,576 | |||||||
|
Total
|
$ | 44,196 | $ | 738 | $ | 43,458 | ||||||
|
2012
|
2011
|
Increase/(Decrease
)
|
||||||||||
|
North America
|
$ | 44,047 | - | $ | 44,047 | |||||||
|
India
|
2,408 | $ | 787 | 1,621 | ||||||||
|
Total
|
$ | 46,455 | $ | 787 | $ | 45,668 | ||||||
|
2012
|
2011
|
Increase/(Decrease
)
|
||||||||||
|
North America
|
$ | 193 | $ | 33 | $ | 160 | ||||||
|
India
|
- | - | - | |||||||||
|
Total
|
$ | 193 | $ | 33 | $ | 160 | ||||||
|
2012
|
2011
|
Increase/(Decrease
)
|
||||||||||
|
North America
|
$ | 1,875 | $ | 2,001 | $ | (126 | ) | |||||
|
India
|
88 | 114 | (26 | ) | ||||||||
|
Other
|
- | (12 | ) | 12 | ||||||||
|
Total
|
$ | 1,963 | $ | 2,103 | $ | (140 | ) | |||||
|
|
March 31,
2012
|
December 31,
2011
|
||||||
|
Cash and cash equivalents
|
$ | 111,654 | $ | 249,466 | ||||
|
Current assets (including cash, cash equivalents, and deposits)
|
6,724,176 | 7,128,916 | ||||||
|
Current liabilities (including short term debt)
|
34,009,413 | 29,428,067 | ||||||
|
Short and long term debt
|
34,619,138 | 29,646,435 | ||||||
|
●
|
expanded our accounting policy and controls organization by creating and filling new positions with qualified accounting and finance personnel;
|
|
●
|
increasing our efforts to educate both our existing and expanded accounting policy and control organization on the application of the internal control structure,
|
|
Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002.
|
|
|
Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
AEMETIS, INC.
|
|||
|
Date: October 31
,
2012
|
By:
|
/s/ E
ric
A. M
c
A
fee
|
|
|
Eric A. McAfee
|
|||
|
Chief Executive Officer
|
|||
|
(Principal Executive Officer)
|
|||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|